Home
Commercial Solutions
Back
Integrated Commercial Services
Back
Advisory Services
Back
Management Consulting
Regulatory Consulting
Specialty Consulting
Canadian Advisory Services
HEOR, Value & Evidence
Patient Services
Back
Access & Hub
Adherence Solutions
Affordability, Co-Pay & PAP
Specialty Pharmacy
In-Home Nursing & Clinical Support
Field Deployment Solutions
Back
Field Deployment Solutions
Medical Deployment Solutions
Learning & Performance Services
Market Access
Back
Market Access Strategies
Market Shaping Activation Model
Market Access & Reimbursement
Market Research & Insights
RWE & HEOR
Pricing & Revenue Management
Back
Global Pricing & Access
Market Access & Reimbursement
收益管理
Research & Insights
Medical Affairs
Back
Medical Affairs Strategy
Integrated Compliance Solutions
Medical Information
Pharmacovigilance
Quality Assurance/Quality Management Systems
Regulatory
Medical Affairs Technology Innovation
Agency Solutions
Back
Patient, Payer & Provider Marketing Agency
Digital Transformation & Innovation
Omnichannel Platform
Trade, Channel & 3PL
Back
Global Channel Management & 3PL
e-Commerce
Data & Analytics
Back
Data & Analytics Solutions
Analytics as a Service
Advanced Analytics
Field Force Optimization Strategies
Integrated Commercial Models
Back
EVERSANA COMPLETE Commercialization®
EVERSANA REIGNITE™
EVERSANA ORCHESTRATE™
EVERSANA COMPLETE Oncology™
Direct-to-Patient Care Model
Value Across Life Cycle
Back
EVERSANA COMPLETE Commercialization®
EVERSANA’s Direct-to-Patient Care Model
Launch Readiness
Product Launch
In Market
Established Brands
Technology & Innovation
Back
NAVLIN
Back
Global Pricing & Access Data
Research & Insights
收益管理
Price & Access Software
ACTICS
Back
Omnichannel Platform
Patient Relationship Management
ACTICS eAccess
Chronic Disease RWD
EVERSANA ORCHESTRATE™
Quality Management Systems
Donor Eligibility System
Solve Commercial Challenges
Back
Assess Commercial Readiness in Europe
Market Shaping Activation Model
Propel Commercialization with D&A
Reach Patients & Sustain Adherence
Penetrate & Expand Markets
Optimize Product Launch
Ensure Market Access
Maintain Safe & Effective Usage
Mobilize High Performing Sales Force
Distribute in Effective & Efficient Ways
Optimize Pricing & Reimbursement
Achieve Stakeholder Intimacy
Therapeutic Expertise
Back
Oncology & Hematology
Neurology & CNS
Rare
Cell & Gene
Digital Medicines
About
Back
Beliefs
Leaders
专家
分支机构
Awards
Events
最新观点
Back
Thought Leadership
Scientific Insights
News
Careers
Search
Select a Region
North America
亚太地区
Europe
North America
Contact
menu
Home
Commercial Solutions
Integrated Commercial Services
Advisory Services
Management Consulting
Regulatory Consulting
Specialty Consulting
Canadian Advisory Services
HEOR, Value & Evidence
Patient Services
Access & Hub
Adherence Solutions
Affordability, Co-Pay & PAP
Specialty Pharmacy
In-Home Nursing & Clinical Support
Field Deployment Solutions
Field Deployment Solutions
Medical Deployment Solutions
Learning & Performance Services
Market Access
Market Access Strategies
Market Shaping Activation Model
Market Access & Reimbursement
Market Research & Insights
RWE & HEOR
Pricing & Revenue Management
Global Pricing & Access
Market Access & Reimbursement
收益管理
Research & Insights
Medical Affairs
Medical Affairs Strategy
Integrated Compliance Solutions
Medical Information
Pharmacovigilance
Quality Assurance/Quality Management Systems
Regulatory
Medical Affairs Technology Innovation
Agency Solutions
Patient, Payer & Provider Marketing Agency
Digital Transformation & Innovation
Omnichannel Platform
Trade, Channel & 3PL
Global Channel Management & 3PL
e-Commerce
Data & Analytics
Data & Analytics Solutions
Analytics as a Service
Advanced Analytics
Field Force Optimization Strategies
Integrated Commercial Models
EVERSANA COMPLETE Commercialization®
EVERSANA REIGNITE™
EVERSANA ORCHESTRATE™
EVERSANA COMPLETE Oncology™
Direct-to-Patient Care Model
Value Across Life Cycle
EVERSANA COMPLETE Commercialization®
EVERSANA’s Direct-to-Patient Care Model
Launch Readiness
Product Launch
In Market
Established Brands
Technology & Innovation
NAVLIN
Global Pricing & Access Data
Research & Insights
收益管理
Price & Access Software
ACTICS
Omnichannel Platform
Patient Relationship Management
ACTICS eAccess
Chronic Disease RWD
EVERSANA ORCHESTRATE™
Quality Management Systems
Donor Eligibility System
Solve Commercial Challenges
Assess Commercial Readiness in Europe
Market Shaping Activation Model
Propel Commercialization with D&A
Reach Patients & Sustain Adherence
Penetrate & Expand Markets
Optimize Product Launch
Ensure Market Access
Maintain Safe & Effective Usage
Mobilize High Performing Sales Force
Distribute in Effective & Efficient Ways
Optimize Pricing & Reimbursement
Achieve Stakeholder Intimacy
Therapeutic Expertise
Oncology & Hematology
Neurology & CNS
Rare
Cell & Gene
Digital Medicines
About
Beliefs
Leaders
专家
分支机构
Awards
Events
最新观点
Thought Leadership
Scientific Insights
News
Careers
Search
Newscenter
Browsing Archive: ImmuneImmune | EVERSANA
Posted on
9 月 20, 2023
9/20/23
A Systematic Literature Review and Network Meta-Analysis of Therapies for Psoriatic Arthritis on Patient-reported Outcomes
Posted on
2 月 1, 2023
2/1/23
Cost effectiveness of Ofatumumab in Comparison With Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
Posted on
2 月 1, 2023
2/1/23
Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review
Posted on
2 月 1, 2023
2/1/23
Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis
Posted on
2 月 1, 2023
2/1/23
Matching-Adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline PASI from week 4-40
Posted on
1 月 25, 2023
1/25/23
Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder
Posted on
10 月 2, 2020
10/2/20
Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany
Posted on
10 月 2, 2020
10/2/20
Network Meta-Analysis of Ulcerative Colitis Pharmacoptherapies: Carryover Effects from Induction and Bias of the Results
Posted on
10 月 2, 2020
10/2/20
Methodological challenges with conducting network meta-analyses assessing long-term comparative efficacy in psoriasis: A critique of assumptions underpinning recent indirect treatment comparisons
Posted on
10 月 2, 2020
10/2/20
Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis
Immune